111 (YI) Competitors

111 logo
$2.87 +0.08 (+2.87%)
As of 11:08 AM Eastern
This is a fair market value price provided by Massive. Learn more.

YI vs. COSM, RDGT, MEDS, HKPD, and MCK

Should you buy 111 stock or one of its competitors? 111's main competitors and comparable companies include Cosmos Health (COSM), Ridgetech (RDGT), Wellgistics Health (MEDS), Hong Kong Pharma Digital Technology (HKPD), and McKesson (MCK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare distributors" industry.

How does 111 compare to Cosmos Health?

111 (NASDAQ:YI) and Cosmos Health (NASDAQ:COSM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

111 has a net margin of -1.01% compared to Cosmos Health's net margin of -33.08%. 111's return on equity of 0.00% beat Cosmos Health's return on equity.

Company Net Margins Return on Equity Return on Assets
111-1.01% N/A -4.86%
Cosmos Health -33.08%-56.88%-18.03%

111 has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Cosmos Health has a beta of 4.73, meaning that its share price is 373% more volatile than the broader market.

21.3% of 111 shares are held by institutional investors. Comparatively, 12.6% of Cosmos Health shares are held by institutional investors. 43.9% of 111 shares are held by insiders. Comparatively, 26.2% of Cosmos Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

111 has higher revenue and earnings than Cosmos Health. 111 is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
111$1.80B0.01-$9.65M-$1.60N/A
Cosmos Health$65.27M0.26-$19.15M-$12.80N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
111
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cosmos Health
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Cosmos Health had 3 more articles in the media than 111. MarketBeat recorded 4 mentions for Cosmos Health and 1 mentions for 111. 111's average media sentiment score of 1.11 beat Cosmos Health's score of -0.18 indicating that 111 is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
111
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cosmos Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

111 beats Cosmos Health on 9 of the 15 factors compared between the two stocks.

How does 111 compare to Ridgetech?

111 (NASDAQ:YI) and Ridgetech (NASDAQ:RDGT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

21.3% of 111 shares are held by institutional investors. Comparatively, 45.3% of Ridgetech shares are held by institutional investors. 43.9% of 111 shares are held by company insiders. Comparatively, 22.6% of Ridgetech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ridgetech has a net margin of 0.00% compared to 111's net margin of -1.01%.

Company Net Margins Return on Equity Return on Assets
111-1.01% N/A -4.86%
Ridgetech N/A N/A N/A

111 has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Ridgetech has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market.

In the previous week, 111 had 1 more articles in the media than Ridgetech. MarketBeat recorded 1 mentions for 111 and 0 mentions for Ridgetech. 111's average media sentiment score of 1.11 beat Ridgetech's score of 0.00 indicating that 111 is being referred to more favorably in the media.

Company Overall Sentiment
111 Positive
Ridgetech Neutral

Ridgetech has lower revenue, but higher earnings than 111.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
111$1.80B0.01-$9.65M-$1.60N/A
Ridgetech$132.16M0.03-$1.25MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
111
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ridgetech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

111 and Ridgetech tied by winning 5 of the 10 factors compared between the two stocks.

How does 111 compare to Wellgistics Health?

111 (NASDAQ:YI) and Wellgistics Health (NASDAQ:MEDS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

21.3% of 111 shares are owned by institutional investors. Comparatively, 5.7% of Wellgistics Health shares are owned by institutional investors. 43.9% of 111 shares are owned by company insiders. Comparatively, 19.5% of Wellgistics Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

111 has a net margin of -1.01% compared to Wellgistics Health's net margin of -564.70%.

Company Net Margins Return on Equity Return on Assets
111-1.01% N/A -4.86%
Wellgistics Health -564.70%N/A -105.00%

111 has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Wellgistics Health has a beta of -3.14, indicating that its share price is 414% less volatile than the broader market.

In the previous week, 111 and 111 both had 1 articles in the media. 111's average media sentiment score of 1.11 beat Wellgistics Health's score of 0.18 indicating that 111 is being referred to more favorably in the media.

Company Overall Sentiment
111 Positive
Wellgistics Health Neutral

111 has higher revenue and earnings than Wellgistics Health. 111 is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
111$1.80B0.01-$9.65M-$1.60N/A
Wellgistics Health$23.34M0.10-$101.28M-$20.41N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
111
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Wellgistics Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

111 beats Wellgistics Health on 9 of the 11 factors compared between the two stocks.

How does 111 compare to Hong Kong Pharma Digital Technology?

111 (NASDAQ:YI) and Hong Kong Pharma Digital Technology (NASDAQ:HKPD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

21.3% of 111 shares are held by institutional investors. 43.9% of 111 shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
111
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Hong Kong Pharma Digital Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Hong Kong Pharma Digital Technology has a net margin of 0.00% compared to 111's net margin of -1.01%.

Company Net Margins Return on Equity Return on Assets
111-1.01% N/A -4.86%
Hong Kong Pharma Digital Technology N/A N/A N/A

Hong Kong Pharma Digital Technology has lower revenue, but higher earnings than 111.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
111$1.80B0.01-$9.65M-$1.60N/A
Hong Kong Pharma Digital Technology$13.43M0.08-$1.14MN/AN/A

111 has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Hong Kong Pharma Digital Technology has a beta of 2.56, meaning that its share price is 156% more volatile than the broader market.

In the previous week, Hong Kong Pharma Digital Technology had 1 more articles in the media than 111. MarketBeat recorded 2 mentions for Hong Kong Pharma Digital Technology and 1 mentions for 111. 111's average media sentiment score of 1.11 beat Hong Kong Pharma Digital Technology's score of 1.00 indicating that 111 is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
111
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hong Kong Pharma Digital Technology
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Hong Kong Pharma Digital Technology beats 111 on 6 of the 10 factors compared between the two stocks.

How does 111 compare to McKesson?

McKesson (NYSE:MCK) and 111 (NASDAQ:YI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

McKesson has a net margin of 1.12% compared to 111's net margin of -1.01%. 111's return on equity of 0.00% beat McKesson's return on equity.

Company Net Margins Return on Equity Return on Assets
McKesson1.12% -202.94% 5.92%
111 -1.01%N/A -4.86%

McKesson currently has a consensus target price of $1,054.12, indicating a potential upside of 0.93%. Given McKesson's stronger consensus rating and higher probable upside, equities analysts clearly believe McKesson is more favorable than 111.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
McKesson
0 Sell rating(s)
4 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.79
111
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

85.1% of McKesson shares are owned by institutional investors. Comparatively, 21.3% of 111 shares are owned by institutional investors. 0.1% of McKesson shares are owned by insiders. Comparatively, 43.9% of 111 shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, McKesson had 9 more articles in the media than 111. MarketBeat recorded 10 mentions for McKesson and 1 mentions for 111. 111's average media sentiment score of 1.11 beat McKesson's score of 0.76 indicating that 111 is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
McKesson
4 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
111
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

McKesson has higher revenue and earnings than 111. 111 is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
McKesson$403.43B0.30$4.76B$38.8926.85
111$1.80B0.01-$9.65M-$1.60N/A

McKesson has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, 111 has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Summary

McKesson beats 111 on 12 of the 16 factors compared between the two stocks.

Get 111 News Delivered to You Automatically

Sign up to receive the latest news and ratings for YI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

YI vs. The Competition

Metric111Healthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$25.22M$9.65B$7.50B$11.74B
Dividend YieldN/A2.55%2.47%4.65%
P/E Ratio-1.7932.8633.0329.92
Price / Sales0.011.948.115.47
Price / CashN/A22.7620.8521.62
Price / Book-0.243.394.423.71
Net Income-$9.65M$329.93M$3.51B$394.40M
7 Day Performance0.70%-5.76%-5.15%-5.09%
1 Month Performance-8.31%-4.60%-6.09%-7.58%
1 Year Performance-24.47%14.73%-1.10%-7.23%

111 Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
YI
111
0.7601 of 5 stars
$2.87
+2.9%
N/A-28.9%$25.22M$1.80BN/A1,063
COSM
Cosmos Health
1.5978 of 5 stars
$2.80
-1.9%
N/A-78.9%$15.18M$73.73MN/A163
RDGT
Ridgetech
0.0793 of 5 stars
$0.99
-3.5%
N/A-99.8%$3.61M$132.16MN/A64
MEDS
Wellgistics Health
0.5415 of 5 stars
$0.76
+17.9%
N/A-97.4%$2.42M$23.34MN/A31
HKPD
Hong Kong Pharma Digital Technology
1.3154 of 5 stars
$1.31
-14.4%
N/A-94.2%$1.16M$13.43MN/A11

Related Companies and Tools


This page (NASDAQ:YI) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners